These alterations, which can include hypermethylation of the H19 locus, can crop up during kidney development.
The Dutch companies will use sequencing- and machine learning-based methods to quantify genomic instability-causing mutations in blood cells.
ArcherDx will develop in vitro diagnostic tests, including companion diagnostics, to run on Illumina's NextSeq 550Dx next-generation sequencing system.
CUTseq uses enzyme-based fragmentation and in vitro transcription to barcode DNA, saving money when preparing 1,000 samples or more.
BTIG gave Centogene a Buy rating, while SVB Leerink and Evercore ISI each gave the company an Outperform rating.
The Genetron Health S5 NGS system is based on the Thermo Fisher Scientific Ion GeneStudio S5 and will be accompanied by Genetron-developed assays.
Clonal hematopoiesis variants appear to outnumber tumor mutations in the plasma of most cancer patients, the investigators found in their study.
The Series A financing will go toward expanding access to its liquid biopsy-based test to more patients in Asia and North America, it said.
Recent studies question the clinical utility of tumor mutational burden as a biomarker for immuno-oncology response, and the FDA clearance includes no therapeutic indications.
The genetic testing firm is offering approximately 2.3 million shares at $11.25 per share and plans to use the funds for general corporate purposes.
The company attributed much of the increase to its work with the VA’s Million Veteran Program, which made up three quarters of its earnings in the quarter.
The Seattle-based immune cell sequencing firm saw sequencing revenues grow 38 percent while development revenues rose 65 percent.
The company expects to launch Signatera for clinical use in colorectal cancer next year and has started to recruit a sales team for the assay.
In a survey conducted by an association working group, 40 percent of respondents said they are already offering TMB, with most others planning to do the same within the year.
Frederick National Lab and Q2 Solutions have been validating the kit as early users and plan to implement it in their clinical trial services.
Due out in December, the Magnis automated library prep instrument is meant to be an affordable and easy way for researchers to use Agilent's SureSelect kits.
Lexent's NGS assay for monitoring response to treatment and minimal residual disease for solid tumors will eventually run on the Illumina NextSeq 550Dx.
The research-use-only system, which has a list price of $299,000, fits with Thermo Fisher's vision of a future of disseminated implementation of NGS.
The firm is looking to expand its sales internationally, as well as in the consumer-initiated market, but is being conservative with revenue growth estimates.
The company said three clinical centers have validated the test in a prospective clinical trial involving more than 10,000 participants.
The Economist reports that it is increasingly easier to analyze the metabolites people give off, potentially revealing personal information about them.
A controversial paper on the gender gap in science has been corrected, according to BuzzFeed News.
The Los Angeles Times reports that only a third of California students meet the state's new science standards.
In Science this week: evidence of interbreeding between the ancestors of West Africans and an unknown archaic human, and more.